Resumen de AcrySof Phakic IOL for Correction of Moderate-to-High Myopia: 1 Year Results

Ramón Ruiz Mesa, F. Pastor-Pascual, M. Angeles de Los Santos Mata, Teresa Ferrer Blasco

• PURPOSE: To evaluate the efficacy, predictability and safety of myopic phakic angle-supported intraocular lens for correction of moderate to high myopia.

  METHODS: In a prospective non comparative interventional case series, outcomes in 42 eyes, with a preoperative mean spherical equivalent of -11.00 diopters (D) ± 2.79, were analyzed 12 months after the implantation of the AcrySof Cachet. They comprised uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), slit-lamp examination, refraction, endothelial cell count, IOL rotation and position.

  RESULTS: The mean UCVA and BCVA after AcrySof Cachet implantation were 0.80±0.25 and 0.92±0.18, respectively (efficacy index: 0.94). No eyes lost ≥1 lines, 16 eyes did not change after surgery, 11 eyes gained 1 line and 15 eyes gained ≥ 1 lines of visual acuity.

  (safety index: 1.08). All eyes were within ±1.00D of the desired refraction and 83.3% within ±0.50D. The mean postoperative spherical equivalent was -0.24±0.36D. The mean percentage change in central endothelial cell density from the preoperative visit to 1 year post-surgery was -6.16±4.29%. The mean value of misalignment was 3.97±2.91 degrees.

  OCT Visante showed a mean central lens-endothelium value of 2.09±0.26 mm, a central lens-anterior crystalline lens capsule value of 0.91±0.18 mm and a lens edge-endothelium of 1.16±0.31 mm. No pupil ovalization, pupillary block, or retinal detachment events were observed.

  CONCLUSIONS: The AcrySof phakic angle-supported lens implantation was a safe, effective, and predictable procedure for the correction of moderate and high myopia